PerkinElmer has named Karl Hecker the new director of R&D for its Boston-based Center of Excellence, the company said this week.
Hecker joins PerkinElmer from Invitrogen and brings more then 20 years of scientific experience in chemistry and biochemistry applications. He holds a PhD in biochemistry from Florida State University, a MS in chemistry from Eastern Illinois University, and master's and BS degrees in chemistry from Johann Wolfgang Goethe University, Frankfurt Germany.
Genetix named Andrew Kellett finance director effective March 27, the company announced last week.
Kellett succeeds Gary Corsi, who leaves the company on January 31.
Kellett is currently a finance director at Quest Diagnostics, where he has worked since February 2000. He has also held senior financial positions with MDC, General Cable, and United Biscuits.
Peter Tolias stepped down as vice-president at Ortho-Clinical Diagnostics on January 6. He said he would be taking time off before starting his next position, which he did not disclose.
Prior to Ortho-Clinical, Tolias was a director at the Center for Applied Genomics at the Public Health Research Institute in New Jersey. He helped found the center in January 2000.
Mary Lipscomb was elected chairman of the board of directors of the National Center for Genome Resources, the NCGR announced this week. Lipscomb's position was effective Nov. 19, 2005, according to the statement.
Lipscomb is chair of the University of New Mexico's department of pathology. She replaces Miguel Rios, who was appointed chairman emeritus.
In addition, NCGR announced the elections to the board of the following: Donald Armstrong, member emeritus of Memorial Sloan-Kettering Cancer Center; Charles Arntzen, co-director of the Center for Infectious Diseases and Vaccinology at Arizona State University; William Beavis, chief scientific officer of NCGR; Michael Cawley, president and CEO of the Samuel Roberts Noble Foundation in Ardmore, Okla; Mark Chandler, chairman and CEO of Biophysical Corp., in Austin; Keith Joiner, dean of University of Arizona's college of medicine; Stuart Kauffman, director of the Institute for Biocomplexity and Informatics at the University of Calgary; Stephen Kingsmore, CEO of NCGR; Teresa Leger de Fernandez of Nordhaus Law Firm in Santa Fe; Rick Lyons of University of New Mexico's Center for Infectious Disease and Immunity; Michael Martin, president of New Mexico State University in Las Cruces, N.M.; Marvin Miller, chairman of Onconova Therapeutics in Livingston, NJ; Van Romero, vice president for research at New Mexico Tech in Socorro, NM; Gloria Sarto, director of the University of Wisconsin Center for Women's Health; Jon Soderstrom, managing director of the Office of Cooperative Research at Yale University; and Terry Yates, vice president or research and economic development at the University of New Mexico.
Lawrence Murphy has joined the board of directors of Third Wave Technologies, the company said this week.
Murphy has been an independent consultant since 1997 advising Jabil, Nokia, Cisco, Hewlett-Packard and other clients, said the statement.
Murphy has also served as executive vice president of Core Industries, a publicly held manufacturing company.
ReliaGene Technologies has released a kit for detecting human male DNA in forensic samples called Y-Detect. The kit amplifies regions on the human Y chromosome from samples as small as 10 picograms of DNA without the removal of female DNA in cases such as sexual assault.
Illumina has begun shipping its Sentrix HumanHap300 Genotyping BeadChips for genome-wide disease association studies.
The platform uses Illumina's Infinium assay method to analyze over 317,000 high-value SNP loci per sample, according to the company. Content is mostly derived from tagSNPs identified and validated in the International HapMap Project, Illumina said.